Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs

Methodology

Last updated: 2026-04-18

5-factor weighted frameworkQuarterly re-evaluationCommission-blind scoring

This page describes how we evaluate telehealth services, GLP-1 programs, and prescription medications across our comparison pages, best-of rankings, and drug catalog. The same framework applies whether the service is a paid affiliate partner or not (see our editorial policy).

The five-factor framework

Every service we review is scored on five factors. Each factor contributes to the overall score with the weighting shown below. We chose this weighting because clinical and pricing transparency matter most to readers; brand polish and marketing matter least.

FactorWeightWhat we check
Clinical model30%Who prescribes (MD/DO/NP/PA), their state licensure, whether the program uses asynchronous-only or includes synchronous visits, how follow-up care is structured, escalation paths for adverse events.
Pricing transparency25%Headline price vs full out-of-pocket, what's included (medication, consultation, follow-up, shipping), how dose escalations affect cost, what happens to billing on cancellation.
State availability and access15%Which states the service operates in, whether intake requires a specific state of residence, whether the service prescribes controlled substances or specialty medications across state lines.
Cancellation and refund terms15%How easy it is to cancel (one-click vs phone-required), refund eligibility, money-back guarantees, what happens to unused medication.
Customer experience15%Intake friction, time-to-first-prescription, shipping speed and packaging, customer support responsiveness, third-party review patterns (Trustpilot, BBB, Reddit) including how the service responds to negative feedback.

How we test

For most services we review, we complete the intake process to first prescription (or to disqualification, when we don't meet criteria). This gives us a primary data on intake friction, clinical screening rigor, and upsell patterns. When we cannot complete the intake (state mismatch, eligibility criteria), we note that and rely on documented intake flows and third-party reports.

We do not fabricate medical history during intake. When a service asks about contraindications, we answer honestly; this means some intakes end in legitimate disqualification, which we report.

How we score and rank

Each factor is scored on a 1-5 scale based on objective criteria documented per category. Scores are aggregated into a weighted total displayed as a 1-5 star rating. We do not round individual factor scores up to inflate totals.

Best-of ranking pages list services in score order, with ties broken by the higher score on the most-relevant factor for that category (e.g., pricing transparency for "cheapest GLP-1 programs", clinical model for "most rigorous weight-loss intake").

When we update reviews

Services change. Prices change. We re-evaluate every review on a quarterly cadence and immediately when we learn of a material change (price update, new offering, FDA action, state availability change). The visible "Last reviewed" date reflects the most recent review of that specific page.

What we do not score on

Drug-page methodology

Drug catalog pages (e.g., Wegovy, Zepbound, finasteride) summarize the FDA prescribing information, peer-reviewed trial data, and clinical guidelines. We do not score drugs against each other — drugs are tools used in clinical decision-making, not consumer products. Comparison pages between drugs (e.g., "Wegovy vs Zepbound") describe trial-supported differences without declaring one "winner" since the right choice is individual.

Insurance coverage methodology

Insurance carrier coverage pages summarize general patterns observed across published formularies, patient reports, and our own intake testing. Coverage within a single carrier varies dramatically by employer plan, region, and formulary tier — we describe representative patterns, not guarantees. Every insurance page includes a prominent disclaimer instructing readers to verify with their specific plan.

Conflicts of interest

glpzoom is independently owned. We have no equity in any telehealth service or pharmaceutical manufacturer. We earn affiliate commissions from many of the services we review (see affiliate disclosure); commissions do not influence ranking or scoring. Editorial staff have no equity or compensation tied to any specific service's performance.

Contact

Methodology questions or to challenge a specific score: [email protected].

We may earn a commission when you click links to partners. Affiliate disclosure.